公开(公告)号：US20180243422A1

公开(公告)日：2018-08-30

申请号：US15788631

申请日：2017-10-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tomomichi FUTO ,  Hikaru TAIRA ,  Seitaro MIZUKAMI ,  Naoyuki MURATA

IPC: A61K47/34 ,  A61K9/50

CPC classification number: A61K47/34 ,  A61K9/19 ,  A61K9/5031 ,  A61K9/5089 ,  A61K38/08 ,  C08J3/005 ,  C08J2367/04 ,  C08J2389/00 ,  C08L67/04 ,  C08L89/00 ,  C08L2666/26

Abstract: The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably releases compound (I) or a salt thereof over a long period of time and exerts medicinal effects of compound (I) or a salt thereof over a long period of time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing frequency of administration, is an excellent formulation as a clinical medicine.

公开(公告)号：US20220251576A1

公开(公告)日：2022-08-11

申请号：US17622580

申请日：2020-06-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoyuki MURATA ,  Sayan CHUANOI ,  Shigeo YANAI

IPC: C12N15/64 ,  C07K14/725 ,  A61P37/00 ,  A61K9/00 ,  A61K9/51 ,  A61K9/08 ,  A61K47/26

Abstract: A novel means for safely and efficiently introducing a target substance such as nucleic acid, protein, or the like into immune cells such as T cell and the like is provided by the present invention. Thus, a system for delivering a target substance into an immune cell, including ultrafine bubble water or ultrafine bubble aqueous solution containing ultrafine bubbles with an average diameter of not more than 200 nm and not containing phospholipid, and an ultrasound generator in combination; a method for increasing the delivery of a nucleic acid or a protein into an immune cell by using the ultrafine bubble water, etc. and ultrasound; and the like are provided.

公开(公告)号：US20220249665A1

公开(公告)日：2022-08-11

申请号：US17622585

申请日：2019-06-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoyuki MURATA ,  Shigeo YANAI

IPC: A61K41/00 ,  C12N15/88 ,  A61K48/00 ,  C12N15/113

Abstract: A novel means for safely and efficiently introducing a target substance such as nucleic acid, protein, or the like into cells (excluding immune cells) is provided by the present invention. Specifically, a system for delivering a target substance into a cell (excluding immune cells), including ultrafine bubble water or ultrafine bubble aqueous solution containing ultrafine bubbles with an average diameter of not more than 200 nm and not containing phospholipid, and an ultrasound generator in combination; a method for increasing the delivery of a nucleic acid, a protein or a low-molecular-weight compound into a cell (excluding immune cells) by using the ultrafine bubble water, etc.; and the like are provided.

公开(公告)号：US20180228732A1

公开(公告)日：2018-08-16

申请号：US15809459

申请日：2017-11-10

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tomomichi FUTO ,  Hikaru TAIRA ,  Seitaro MIZUKAMI ,  Naoyuki MURATA

IPC: A61K9/16 ,  A61K9/00

CPC classification number: A61K9/1647 ,  A61K9/0024

Abstract: The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic acid-glycolic acid copolymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably release compound (I) or a salt thereof for a long time and exerts a medicinal effect of compound (1) or a salt thereof for a long time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing the number of administration times, is an excellent formulation as a clinical medicine.

公开(公告)号：US20210052872A1

公开(公告)日：2021-02-25

申请号：US16958388

申请日：2018-12-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoyuki MURATA ,  Shigeo YANAI

IPC: A61M37/00

Abstract: The present invention provides a safer novel opening system with highly broad utility for a blood-brain barrier (BBB), containing nano-bubble water or nano-bubble aqueous solution containing nano-bubbles having an average diameter of not more than 200 nm, and an ultrasound generating apparatus in combination; a method for opening BBB, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound; and a method for increasing BBB permeability of a drug, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound.

公开(公告)号：US20170189943A1

公开(公告)日：2017-07-06

申请号：US15314187

申请日：2015-05-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoyuki MURATA ,  Jiichi ARAI

IPC: B08B3/10 ,  B82Y30/00 ,  C02F1/24 ,  A61L2/02 ,  A61L9/012

CPC classification number: B08B3/10 ,  A61K9/0019 ,  A61K33/00 ,  A61K47/02 ,  A61K47/20 ,  A61K47/32 ,  A61K47/34 ,  A61L2/02 ,  A61L9/012 ,  B82Y30/00 ,  C02F1/24 ,  C02F1/68 ,  C02F2303/04

Abstract: A novel technique is provided for preserving a liquid pharmaceutical preparation safely and stably. The nano-bubble water of the present invention, which is produced in the presence of a surfactant, a hydrophilic resin and/or an electrolyte and contains not less than 2.0×108 bubbles/mL of nano-bubbles, shows a superior antibacterial action, and can be used as a base of a liquid pharmaceutical preparation showing safe and stable preservation property.